Veeva Vault Signal versnelt de signaalbeheerprocessen van detectie via risico-evaluatie en mitigatie
BARCELONA, Spanje– (BUSINESS WIRE) – Veeva Systems (NYSE: VEEV) heeft vandaag Veeva Vault Signal aangekondigd, de eerste oplossing in de branche die naadloos signalen van identificatie door risicobeoordeling en -beperking beheert. Vault Signal verenigt signaalbeheerprocessen zodat farmacovigilantieteams gemakkelijk veiligheidssignalen kunnen beheren met meer zichtbaarheid over de gehele signaalworkflow. Samen met Vault Safety, Vault SafetyDocs en Vault Safety.AI, biedt Veeva het enige uitgebreide pakket cloudapplicaties op één cloudplatform om de levenscyclus van drugsveiligheid te beheren – van inname van cases tot signaaldetectie en planning van risicobeheer.
Veeva to Deliver End-to-End Safety Signal and Risk Management
Veeva Vault Signal will accelerate signal management processes from detection through risk evaluation and mitigation
BARCELONA, Spain–(BUSINESS WIRE)– Veeva Systems (NYSE: VEEV) today announced Veeva Vault Signal, the industry’s first solution that seamlessly manages signals from identification through risk evaluation and mitigation. Vault Signal unifies signal management processes so pharmacovigilance teams can easily manage safety signals with greater visibility across the entire signal workflow. Together with Vault Safety, Vault SafetyDocs, and Vault Safety.AI, Veeva offers the only comprehensive suite of cloud applications on a single cloud platform to manage the drug safety lifecycle – from case intake to signal detection and risk management planning.
“Veeva Vault Signal is welcome news for companies looking for an efficient, one-stop solution for drug safety,” said Marc Morris, vice president, safety and pharmacovigilance at Apellis Pharmaceuticals. “Streamlining adverse reaction data, signal analysis, and action with one platform will make safety risk management simpler and faster, as well as free up my group’s resources.”
Vault Signal analyzes and segments adverse event data from customers’ safety databases and external global health authorities. Pharmacovigilance teams can more readily identify and manage signals, improving future risk mitigation. Vault Signal is easily tailored to align with every signal management process and meet the needs of any business, from large pharmaceutical companies to emerging biotechs.
“Veeva is delivering a modern approach to signal management that will speed up how pharmacovigilance teams analyze data, detect and evaluate signals, and perform risk mitigation,” said Kelly Traverso, vice president of safety strategy at Veeva. “Veeva Vault Signal will give organizations the full visibility and traceability they need to drive compliance in patient safety.”
In other news today, Veeva announced Veeva Vault Product Surveillance, a new cloud application for medical device and diagnostics to simplify and standardize the postmarket surveillance process. Read today’s press release to learn more.
Vault Signal, Vault Safety.AI, Vault Safety, and Vault SafetyDocs are part of the Veeva Vault Safety Suite to manage end-to-end drug safety processes. Vault Signal is planned for availability in the U.S. and Europe in April 2021.
Learn more about Vault Signal at the upcoming virtual Veeva Safety Forum, 19 May. The event is open to Veeva customers and invited guests. Register and view the agenda at veeva.com/SafetyForum.
For more on Veeva Vault Signal, visit: veeva.com/eu/VaultSignal
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veeva_eu on Twitter: twitter.com/veeva_eu
Like Veeva on Facebook: facebook.com/veevasystems
About Veeva Systems
Veeva Systems Inc. is the leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 850 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com/eu.
This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-K for the period ended January 31, 2020. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.
® 2020 Veeva Systems Inc. All rights reserved. Veeva and the Veeva logo are trademarks of Veeva Systems Inc.
Veeva Systems Inc. owns other registered and unregistered trademarks.